ICML 2019 | Zanubrutinib plus obinutuzumab: CLL, SLL & FL

Constantine Tam

Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of zanubrutinib plus obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed/refractory follicular lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video